With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.351498-10-7,6,6′-((1E,1’E)-((2,3-Dimethylbutane-2,3-diyl)bis(azanylylidene))bis(methanylylidene))bis(2,4-di-tert-butylphenol),as a common compound, the synthetic route is as follows.
Preparation of Cobalt(II) ComplexA 50 mL flask was charged with N,N’-bis(3,5-di-tert-butylsalicylidene)-l, 1,2,2- tetramethylethenediamine (0.4302 g, 0.78 mmol, 1.0 equiv), EtOH (17 mL), and Co(OAc)2 (0.1385 g, 0.78 mmol, 1.0 equiv). The mixture was degassed and then heated to reflux under nitrogen for 3 h, cooled to room temperature. The precipitate was filtered and the purple solid was washed with EtOH (10 mL) and dried under high vacuum to give 0.3533 g (75%) of the cobalt(II) complex., 351498-10-7
The synthetic route of 351498-10-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; VITAE PHARMACEUTICALS, INC.; CLAREMON, David, A.; WO2010/91067; (2010); A2;,
Chiral Catalysts
Chiral catalysts – SlideShare